Skip to main content
. Author manuscript; available in PMC: 2011 Nov 16.
Published in final edited form as: Cancer Cell. 2010 Nov 16;18(5):411–422. doi: 10.1016/j.ccr.2010.10.024

Figure 2. SAH-p53-8 targets both HDM2 and HDMX in situ.

Figure 2

SJSA-X cells were treated for 12 hours with either vehicle, FITC-SAH-p53-8 (15 µM), or FITC-SAH-p53-8F19A (15 µM). Anti-FITC immunoprecipitates from cellular extracts were subjected to HDM2 and HDMX western analyses, with β-actin used as a loading control. The presence of FITC-labeled peptide in the extracts was detected by a fluorescence scan of the immunoblot.